Pancreatic Cancer

Previous studies found calcium channel blockers could prevent pancreatic cancer, but have neglected to consider the effects of short-acting CCBs.

The US Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera) for the treatment of somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors in adults.

ASCO clinical practice guidelines recommend resection followed by treatment with gemcitabine and capecitabine as the standard of care; however, neoadjuvant therapy is also considered an appropriate alternative.

Neoadjuvant therapy is an attractive approach with the promise of clinical benefit for patients with surgically resectable pancreatic cancer. However, clinical trial results in support of this approach remain unconvincing.

Researchers are proposing the consideration of expanding criteria for liver debulking in pancreatic neuroendocrine tumors to include a threshold of greater than 70% debulking, intermediate grade tumors, positive margins, parenchyma-sparing resections, and extrahepatic metastases.

In this review, we focus on the treatment of well-differentiated early and metastatic PNETs, emphasizing current controversies, recent advances in therapy, and the multidisciplinary approach required for optimal treatment.

Germline mutations in pancreatic cancer susceptibility genes were commonly identified in a group of patients with pancreatic cancer who did not report a significant family history of cancer, according to the results of a single-center study.

This video reviews the conflicting data and perspectives regarding the use of radiotherapy in unresectable pancreatic cancer.

This video examines the role of immunotherapy in pancreatic cancer, highlighting the resistance to novel treatments in this setting and trials attempting to confront this problem.

This video examines the management of resectable pancreatic cancer, including how this type of disease is best defined, the latest standard of care in the adjuvant setting, and emerging trends in surveillance.

Adding PEGPH20 to nab-paclitaxel and gemcitabine improved progression-free survival in patients with untreated, metastatic pancreatic ductal adenocarcinoma.

In this article we will discuss the definitions of resectability, describe the current diagnostic tests for pancreatic cancer, and review strategies for maximizing treatment outcomes in patients with resectable pancreatic cancer.

This video highlights the evolution of stereotactic body radiation therapy in the treatment of pancreatic cancer.

ASCO updated a 2016 guideline regarding resected pancreatic cancer to include treatment with adjuvant chemotherapy with gemcitabine and capecitabine.

Cigarette smoking was associated with an almost 40% reduction in survival among patients with pancreatic cancer.

In this article, we review seminal articles that have evaluated the molecular architecture of pancreatic cancer. We compare the methods used and the molecular subtypes defined, and assess the predominant subgroups in order to better understand which therapies may improve patient outcomes.

The onset of diabetes or the rapid deterioration of existing diabetes may be an early signal for pancreatic cancer for some patients, according to the results of a study presented at the European Cancer Congress.

The regular use of aspirin reduced the risk for pancreatic cancer by almost 50%, according to the results of a Chinese study.

The Pancreatic Cancer Action Network is aiming to improve the lives of patients diagnosed with the third-leading cause of cancer-related death with a new precision drug trial.

These guidelines review the use of radiation, chemotherapy, and surgery in borderline and unresectable pancreas cancer. Radiation technique, dose, and targets were evaluated, as was the recommended chemotherapy, administered either alone or concurrently with radiation. This report will aid clinicians in determining guidelines for the optimal treatment of borderline and unresectable pancreatic cancer.

Researchers are reporting they have identified ERCC3 as a new target for pancreatic cancer and demonstrated the effects are extremely strong in a molecularly defined subset of patients.

The ESPAC-4 trial found that adding capecitabine to gemcitabine in patients with resected pancreatic cancer resulted in an improved estimated 5-year survival rate.

Use of hypofractionated chemoradiation prior to pancreatoduodenectomy resulted in similar resection rates and outcomes vs standard fractionation.

Annual screening of people at high risk for pancreatic ductal adenocarcinoma (PDAC) because of CDKN2A mutations was relatively successful and allowed for the detection of disease in time to perform surgery.

For the first time, researchers suggest that underlying genetic mutations may cause pancreatic adenocarcinoma tumors to stiffen up and produce a dangerous thickening and scarring of the tissue around them.

Researchers have identified two species of bacteria linked with periodontal disease in healthy individuals that are associated with a risk of developing pancreatic cancer.

Higher preoperative levels of serum albumin were significantly associated with greater overall survival among patients undergoing resection of pancreatic adenocarcinoma.

An integrated genomic analysis has found that pancreatic cancer can be divided into four specific subtypes based on molecular characteristics. This division could help guide treatment decisions and future research avenues into this difficult malignancy.

Pancreatic cancer patients who received adjuvant therapy at a high-volume center had superior overall survival vs patients who were treated in a community setting.

Nanoliposomal irinotecan combined with fluorouracil/leucovorin improved overall survival in metastatic pancreatic cancer patients who have already been treated with gemcitabine.